Rockville, Maryland, United States – September 22, 2026 – Longevity drug development is increasingly moving toward clinically defined diseases and measurable biological endpoints rather than broad claims about extending human life. Insilico Medicine's investigational drug rentosertib, currently in Phase 3 development for idiopathic pulmonary fibrosis, is being evaluated...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek